Eltrombopag 25 mg is used to treat thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.

Eltrombopag instructions

Product Name: LuciElo

Manufacturer: Lucius Pharmaceuticals

Chinese name: Eltrombopag

English name: Eltrombopag olamine

Drug approval number: 05 L 0969/23

 

【Summary】

Eltrombopag is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have not responded adequately to corticosteroids, immunoglobulins, or splenectomy.

Eltrombopag should only be used in patients with ITP whose degree of thrombocytopenia and clinical circumstances increase the risk of bleeding. Eltrombopag should not be used with the intent to normalize platelet counts. Eltrombopag has promise in treating aplastic anemia.

Eltrombopag can also be used to treat thrombocytopenia in patients with chronic hepatitis C.

 

【Indications】

Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.

 

【Specification】

25mg/tablet, 28 tablets/box.

 

【Storage】

Store at 20°C to 25°C (68°C to 77°F); short-distance transport is permitted at a temperature range of 15 to 30°C (59–86°F).

 

【Usage and Dosage】

1. The starting dose of eltrombopag is 50 mg once a day; for Oriental patients or patients with moderate or severe hepatic impairment, the starting dose is 25 mg once a day, administered on an empty stomach (1 or 2 hours before meals).

2. A 4-hour interval is allowed between eltrombopag and other drugs, foods, or polyvalent cations (e.g., iron, calcium, aluminum, magnesium, selenium, and zinc) additives. To reduce the risk of bleeding, adjust the daily dose to achieve and maintain a platelet count of ≥50X109/L. The daily dose should not exceed 75 mg.

3. Take it for two weeks, and increase the dose to a maximum of 150 mg per day in two-week cycles. The primary endpoint is blood response, and the first assessment will be conducted after 12 weeks. If no blood response is observed after 16 weeks, treatment will be stopped.

 

【Adverse Reactions】

The most common adverse reactions are: nausea, vomiting, menorrhagia, myalgia, paresthesia, cataracts, dyspepsia, ecchymosis, thrombocytopenia, increased ALT/AST, and conjunctival hemorrhage.

 

【Warnings and Precautions】

1. A 4-hour interval is allowed between eltrombopag and other medications, foods, or polyvalent cation (e.g., iron, calcium, aluminum, magnesium, selenium, and zinc) additives.

2. To reduce the risk of bleeding, adjust the daily dose to achieve and maintain a platelet count ≥ 50×10^9/L.

3. The maximum daily dose is recommended not to exceed 75 mg.

4. Eltrombopag should also be discontinued if important liver function test abnormalities or platelet count overreaction occur.

 

【Drug Interactions】

1. Eltrombopag is an inhibitor of the OATP1B1 transporter. Closely monitor patients for signs and symptoms of overexposure to OATP1B1 substrates, such as rosuvastatin, and consider reducing the dose of these drugs.

2. Polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) significantly reduce the absorption of eltrombopag; eltrombopag must not be taken within 4 hours of any drug containing polyvalent cations such as antacids, dairy products, and mineral supplements.

 

[Special Populations]

Pregnancy: May cause fetal harm.

Nursing mothers: Eltrombopag should be discontinued.